For example, in ongoing clinical trials in hepatocellular carcinoma, a clinical response has been seen with PD-L1 inhibition without a clear predictive role of the PD-L1 expression, with an accelerated FDA approval for nivolumab as a second line therapy without restriction by the PD-L1 status [8,9]. This evidence concerns the gene CD274 and hepatocellular carcinoma.